



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Azintuxizumab vedotin

Cat. No.:	HY-P99454
CAS No.:	1826819-58-2
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells ^[1] .
IC ₅₀ & Target	CD2 subset 1 ^[1]
In Vitro	Azintuxizumab vedotin (ABBV-838) is an ADC comprising a humanized recombinant immunoglobulin G1κ directed against a unique epitope of CD2 subset 1 (CS1, also known as SLAMF7) conjugated to the cytotoxic monomethyl auristatin E (MMAE) through a valine-citrulline linker^[1]. Azintuxizumab vedotin shows potent cytotoxic activity against cancer cells that expressed CS1^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Azintuxizumab vedotin (ABBV-838) shows single-agent antitumor activity in mouse models using human myeloma xenografts^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Vij R, et al. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 May 15;26(10):2308-2317.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA